Found 55 Enz. Inhib. hit(s) with all data for entry = 50001583 
Affinity DataIC50: 110nMAssay Description:Inhibition of human HIF-PHD2 assessed as reduction in HIF1-alpha binding to VBC complex using biotin-labeled HIF1-alpha peptide as substrate preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 120nMAssay Description:Inhibition of human HIF-PHD2 assessed as reduction in HIF1-alpha binding to VBC complex using biotin-labeled HIF1-alpha peptide as substrate preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 190nMAssay Description:Inhibition of human HIF-PHD2 assessed as reduction in HIF1-alpha binding to VBC complex using biotin-labeled HIF1-alpha peptide as substrate preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 210nMAssay Description:Inhibition of human HIF-PHD2 assessed as reduction in HIF1-alpha binding to VBC complex using biotin-labeled HIF1-alpha peptide as substrate preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 220nMAssay Description:Inhibition of human HIF-PHD2 assessed as reduction in HIF1-alpha binding to VBC complex using biotin-labeled HIF1-alpha peptide as substrate preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 290nMAssay Description:Inhibition of human HIF-PHD2 assessed as reduction in HIF1-alpha binding to VBC complex using biotin-labeled HIF1-alpha peptide as substrate preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 300nMAssay Description:Inhibition of PHD2 (181 to 426 residues) (unknown origin) using biotinylated CODD peptide as substrate preincubated for 15 mins followed by substrate...More data for this Ligand-Target Pair
3D Structure (crystal)
Affinity DataIC50: 370nMAssay Description:Inhibition of human HIF-PHD2 assessed as reduction in HIF1-alpha binding to VBC complex using biotin-labeled HIF1-alpha peptide as substrate preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 450nMAssay Description:Inhibition of human HIF-PHD2 assessed as reduction in HIF1-alpha binding to VBC complex using biotin-labeled HIF1-alpha peptide as substrate preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 650nMAssay Description:Inhibition of human HIF-PHD2 assessed as reduction in HIF1-alpha binding to VBC complex using biotin-labeled HIF1-alpha peptide as substrate preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 720nMAssay Description:Inhibition of human HIF-PHD2 assessed as reduction in HIF1-alpha binding to VBC complex using biotin-labeled HIF1-alpha peptide as substrate preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 730nMAssay Description:Inhibition of human HIF-PHD2 assessed as reduction in HIF1-alpha binding to VBC complex using biotin-labeled HIF1-alpha peptide as substrate preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 730nMAssay Description:Inhibition of human HIF-PHD2 assessed as reduction in HIF1-alpha binding to VBC complex using biotin-labeled HIF1-alpha peptide as substrate preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 820nMAssay Description:Inhibition of human HIF-PHD2 assessed as reduction in HIF1-alpha binding to VBC complex using biotin-labeled HIF1-alpha peptide as substrate preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 850nMAssay Description:Inhibition of human HIF-PHD2 assessed as reduction in HIF1-alpha binding to VBC complex using biotin-labeled HIF1-alpha peptide as substrate preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 1.20E+3nMAssay Description:Inhibition of human HIF-PHD2 assessed as reduction in HIF1-alpha binding to VBC complex using biotin-labeled HIF1-alpha peptide as substrate preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 1.60E+3nMAssay Description:Inhibition of human HIF-PHD2 assessed as reduction in HIF1-alpha binding to VBC complex using biotin-labeled HIF1-alpha peptide as substrate preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 2.40E+3nMAssay Description:Inhibition of human HIF-PHD2 assessed as reduction in HIF1-alpha binding to VBC complex using biotin-labeled HIF1-alpha peptide as substrate preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 2.50E+3nMAssay Description:Inhibition of human HIF-PHD2 assessed as reduction in HIF1-alpha binding to VBC complex using biotin-labeled HIF1-alpha peptide as substrate preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 6.50E+3nMAssay Description:Inhibition of human HIF-PHD2 assessed as reduction in HIF1-alpha binding to VBC complex using biotin-labeled HIF1-alpha peptide as substrate preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 7.10E+3nMAssay Description:Inhibition of human HIF-PHD2 assessed as reduction in HIF1-alpha binding to VBC complex using biotin-labeled HIF1-alpha peptide as substrate preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 7.50E+3nMAssay Description:Inhibition of human HIF-PHD2 assessed as reduction in HIF1-alpha binding to VBC complex using biotin-labeled HIF1-alpha peptide as substrate preincub...More data for this Ligand-Target Pair
Affinity DataIC50: 1.60E+4nMAssay Description:Inhibition of human HIF-PHD2 assessed as reduction in HIF1-alpha binding to VBC complex using biotin-labeled HIF1-alpha peptide as substrate preincub...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of CYP2D6 in human liver microsomes by LC-MS/MS analysisMore data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of CYP2C9 in human liver microsomes by LC-MS/MS analysisMore data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of CYP3A4 in human liver microsomes using midozolam as substrate by LC-MS/MS analysisMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Japan Tobacco
Curated by ChEMBL
Japan Tobacco
Curated by ChEMBL
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of human ERG expressed in HEK293 cells at holding potential of -80 mV by whole cell patch clamp methodMore data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of CYP2C8 in human liver microsomes by LC-MS/MS analysisMore data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of CYP3A5 in human liver microsomes using midazolam as substrate by LC-MS/MS analysisMore data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of CYP2C19 in human liver microsomes by LC-MS/MS analysisMore data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of CYP2A6 in human liver microsomes by LC-MS/MS analysisMore data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of CYP2B6 in human liver microsomes by LC-MS/MS analysisMore data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of CYP1A2 in human liver microsomes by LC-MS/MS analysisMore data for this Ligand-Target Pair
Affinity DataEC50: >3.00E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 1.30E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 5.80E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 5.70E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 5.80E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 1.40E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 1.50E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 1.20E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 2.10E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 9.30E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 4.20E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: >3.00E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: >3.00E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: >3.00E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 7.90E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: >3.00E+4nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
Affinity DataEC50: 4.70E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO release after 24 hrs by ELISAMore data for this Ligand-Target Pair
